HIV Vaccine Awareness Day 2014

Comments

Post a Comment

Popular posts from this blog

Coronavirus and Vaccine Development

Coronavirus Vaccine Update: In addition to VBI Vaccines Inc. (Ottawa, Canada), the following firms are as of 27 March 2020 beginning Phase 1 testing Phase I vaccine candidates   Company:  Moderna Vaccine candidate:  mRNA-1273 Details:  Moderna is the Massachusetts-based biotech company behind mRNA-1273, a vaccine candidate developed using prior studies of related coronaviruses, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Study Design:  A Phase 1, open-label, dose-ranging clinical trial of 45 healthy participants between 18-55 years old Institution:   Kaiser Permanente Washington Health Research Institute Status:  Recruiting completed 19 March 2020 ClinicalTrials.gov Identifier:   NCT04283461 Funding:  NIAID   Company:  CanSino Biologics Vaccine candidate:  Ad5-nCoV Details:  China’s CanSino Biologics has developed a recombinant novel coronavirus vaccine that incorporates...
Read more

HepB and Autism

The paper by Gallagher and Goodman published in 2010 generated some online discussions. Since I could not get the original paper, I will repost some of the comments made by others. A post made in  https://leftbrainrightbrain.co.uk/2009/09/17/another-weak-study-proves-vaccines-cause-autism/  shows an analysis of the study and subsequent comments made. Thank you. What did they do? They looked at data from the National Health Interview Studies, and looked at autism and hepatitis B vaccination. They used surveys from 1997 to 2002, with children aged from 3 to 17. Mr. Kirby was kind enough to post an  image of the poster  to the EOHarm group. The autism group had 33 kids total. Of these, 9 of 31 (29%) were given the HepB vaccine. Compare this to 1,258 of 7,455 (17%) of the non-autism group who were given the HepB. 9 out of 31. Are the red flags up yet? They should be. Take for example kids aged 17 in the 1997 survey. When were they born? That’s right, 1...
Read more

Chimp Adenovirus -based Ebola vaccine-Looks promising

A promising new study shows that a recombinant chimp adenovirus-3 vaccine vector carrying the surface glycoproteins of Zaire and Sudan strains of Ebola virus was safe and immunogenic in 20 volunteers. There were 11 women and 9 men in the study and the ages ranged from 25-50. Results 1. What looked really promising was that in about 70-90% of the participants, the vaccine induced antibodies to  Zaire and Sudan glycoproteins. 2. Glycoprotein-specific memory CD4 and CD8 T cell responses were polyfunctional and the vaccine elicited high proportions of CD8 cells co-producing interferon-g and TNF. 3. Pre-existing antibodies against adenovirus-3 did not significantly correlated with the magnitude of vaccine-induced memory CD4 T cell response. Remarks * While the CD4 T cell shows no significant change in cytokine response with increased particle units, the polyfunctionality of CD8 T cells shows a significant change. * The graphs representing "Total Cytokine Response shown a...
Read more